Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Johnson & Johnson Medtech reportedly could sell DePuy Synthes to Apollo

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at massdevice.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

Johnson & Johnson MedTech is reportedly in talks to sell its DePuy Synthes orthopedics business, specifically the hips and knees unit, to Apollo Global Management for around $20 billion as part of a planned spin-off by mid-2027.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The sale of DePuy Synthes signals private equity is ready to buy major medtech OEMs, shaking the vendor landscape. You in medtech should prepare for new buyers disrupting traditional supply chains and customers.

◆ Coverage

2 sources · 14 Sep 2026

◆ Related on Wire

◆ Topics

Medtechmedtechprivate-equitym-aorthopedicsj-j